Related Experiment Video
Updated: Aug 16, 2026

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
Published on: April 11, 2025
Nanoparticle-enabled CD40 silencing programs immune tolerance via a DC-Treg-Breg axis in autoimmune myocarditis
Meiling Yu1,2,3, Huizhu Tan1,2, Kuirong Mao1,2
1Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, First Hospital of Jilin University, Changchun, Jilin, 130062, China.
None:
Autoimmune myocarditis is a severe inflammatory heart disease that can progress to dilated cardiomyopathy and heart failure, while disease-modifying therapies remain limited. Dysregulated activation of antigen-presenting cells, particularly dendritic cells (DCs), disrupts immune tolerance and drives pathogenic cardiac inflammation. Here, we report a nanoparticle-enabled CD40 silencing strategy for immune tolerance programming in experimental autoimmune myocarditis. Using a polymer-lipid hybrid siRNA formulation, we achieved sustained CD40 silencing in myeloid antigen-presenting cells and induced functional reprogramming of DCs toward a tolerogenic state. This intervention established a coordinated DC-centered regulatory circuit, characterized by expansion of Foxp3+ regulatory T cells and IL-10-producing regulatory B cells, together with suppression of pathogenic Th17 responses. Functionally, siCD40/NP treatment attenuated myocardial inflammation, limited chronic fibrotic remodeling, and preserved ventricular function without evidence of overt systemic toxicity. Notably, regulatory B cells were enriched in cardiac-draining lymphoid tissues during the chronic phase, suggesting a spatially organized tolerance mechanism that contributes to durable disease control. Collectively, these findings identify nanoparticle-enabled CD40 silencing as a materials-based strategy for immune tolerance programming and highlight antigen-presenting cell reprogramming as a promising design principle for immunoregulatory biomaterials in inflammatory heart disease.

